Deutsch English Français

Contact

EP1447092

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP1447092

EP1447092 - WT1 anti-tumour vaccine adjuvanted with BCG-cell wall skeleton [Right-click to bookmark this link]
Former [2004/34]	METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
	[2010/45]
Status	The application is deemed to be withdrawn Status updated on 07.10.2011 Database last updated on 20.05.2024
Most recent event Tooltip	07.10.2011	Application deemed to be withdrawn	published on 09.11.2011 [2011/45]
Applicant(s)	For all designated states Sugiyama, Haruo 2-19-30, Senbanishi Minoo-shi Osaka 562-0036 / JP
	For all designated states Azuma, Ichiro 3-2, Makomanai-Kamimachi 5-chome, Minami-ku Sapporo-shi Hokkaido 005-0012 / JP
	[N/P]
Former [2004/34]	For all designated states Sugiyama, Haruo 2-19-30, Senbanishi Minoo-shi, Osaka 562-0036 / JP
	For all designated states Azuma, Ichiro 3-2, Makomanai-Kamimachi 5-chome, Minami-ku Sapporo-shi Hokkaido 005-0012 / JP
Inventor(s)	01 / see applicant ...
	[2004/34]
Representative(s)	Vossius & Partner Patentanwälte Rechtsanwälte mbB Siebertstrasse 3 81675 München / DE
	[N/P]
Former [2008/35]	Vossius & Partner Siebertstrasse 3 81675 München / DE
Former [2004/34]	VOSSIUS & PARTNER Siebertstrasse 4 81675 München / DE
Application number, filing date	02800255.8	27.09.2002
	[2004/34]
	WO2002JP09997
Priority number, date	JP20010301224	28.09.2001 Original published format: JP 2001301224
	[2004/34]
Filing language	JA
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO03028758
	Date:	10.04.2003
	Language:	EN
	[2003/15]
	Type:	A1 Application with search report
	No.:	EP1447092
	Date:	18.08.2004
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 10.04.2003 takes the place of the publication of the European patent application.
	[2004/34]
Search report(s)	International search report - published on:	JP	10.04.2003
	(Supplementary) European search report - dispatched on:	EP	12.06.2007
Classification	IPC:	A61K39/00, A61K45/00, A61P35/00	[2004/34]
	CPC:	A61P35/00 (EP); A61K39/001178 (EP,US); A61P37/04 (EP); A61P43/00 (EP); A61K2039/545 (EP,US); A61K2039/55594 (EP,US)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, SK, TR [2004/34]
Extension states	AL	Not yet paid
	LT	Not yet paid
	LV	Not yet paid
	MK	Not yet paid
	RO	Not yet paid
	SI	Not yet paid
Title	German:	WT1 Antitumorimpfstoff kombiniert mit BCG-Zellwandskelett als Adjuvans	[2010/45]
	English:	WT1 anti-tumour vaccine adjuvanted with BCG-cell wall skeleton	[2010/45]
	French:	Vaccin antitumoral WT1 combiné au squelette de paroi cellulaire de BCG en tant qu' adjuvant	[2010/45]
	Former [2004/34]	NEUES VERFAHREN ZUR INDUKTION VON ANTIGENSPEZIFISCHEN T-ZELLEN
	Former [2004/34]	METHODS OF INDUCING ANTIGEN-SPECIFIC T CELLS
	Former [2004/34]	METHODES D'INDUCTION DE LYMPHOCYTES T SPECIFIQUES D'UN ANTIGENE
Entry into regional phase	28.04.2004	Translation filed
	28.04.2004	National basic fee paid
	28.04.2004	Search fee paid
	28.04.2004	Designation fee(s) paid
	28.04.2004	Examination fee paid
Examination procedure	10.03.2003	Request for preliminary examination filed International Preliminary Examining Authority: JP
	28.04.2004	Amendment by applicant (claims and/or description)
	28.04.2004	Examination requested [2004/34]
	06.02.2008	Despatch of a communication from the examining division (Time limit: M04)
	09.06.2008	Reply to a communication from the examining division
	20.10.2010	Cancellation of oral proceeding that was planned for 28.10.2010
	28.10.2010	Date of oral proceedings (cancelled)
	05.01.2011	Communication of intention to grant the patent
	17.05.2011	Application deemed to be withdrawn, date of legal effect [2011/45]
	22.06.2011	Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2011/45]
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 06.02.2008
Fees paid	Renewal fee
	30.09.2004	Renewal fee patent year 03
	30.09.2005	Renewal fee patent year 04
	29.09.2006	Renewal fee patent year 05
	28.09.2007	Renewal fee patent year 06
	31.03.2008	Renewal fee patent year 07
	24.09.2009	Renewal fee patent year 08
	23.09.2010	Renewal fee patent year 09
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[A]WO9003183 (UNIV SOUTHERN CALIFORNIA [US]) [A] 1-25 * page 10 *;
		[X]WO0026249 (IMP COLLEGE INNOVATIONS LTD [GB], et al) [X] 1-25 * page 9 * * page 20 *;
		[A]EP1097715 (HAYASHI AKIRA [JP], et al) [A] 1-25* the whole document *;
		[X]WO0162920 (CORIXA CORP [US]) [X] 1-25 * page 60 *;
		[A] - YASUMOTO K ET AL, "NONSPECIFIC ADJUVANT IMMUNO THERAPY OF LUNG CANCER WITH CELL WALL SKELETON OF MYCOBACTERIUM-BOVIS BCG", CANCER RESEARCH, (1979), vol. 39, no. 8, ISSN 0008-5472, pages 3262 - 3267, XP002435122 [A] 1-25 * the whole document *
		[T] - NAKAJIMA HIROKO ET AL, "WT1 peptide vaccination combined with BCG-CWS is more efficient for tumor eradication than WT1 peptide vaccination alone", CANCER IMMUNOLOGY IMMUNOTHERAPY, (200407), vol. 53, no. 7, ISSN 0340-7004, pages 617 - 624, XP002435123 [T] 1-25 * the whole document * DOI: http://dx.doi.org/10.1007/s00262-003-0498-0
	International search	[Y]JPS6122018 (GREEN CROSS CORP);
		[Y]WO9602555 (UNIV IOWA RES FOUND [US]);
		[Y]WO9944634 (OHIO MED COLLEGE [US], et al);
		[Y]WO0018795 (CORIXA CORP [US], et al);
		[Y]WO0041463 (SMITHKLINE BEECHAM BIOLOG [BE], et al);
		[Y]WO0044349 (IDEA AG [DE], et al);
		[Y]JP2001089389 (SUMITOMO PHARMA);
		[Y]WO0162920 (CORIXA CORP [US]);
		[YE]WO02079253 (SUGIYAMA HARUO [JP]);
		[T] - TSUBOI A. ET AL, "Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues.", CAPLUS, Database accession no. (2002:880632), XP003016309
		[ ] - CANCER IMMUNOL. IMMUNOTHER., (200212), vol. 51, no. 11-12, pages 614 - 620, XP002961732 DOI: http://dx.doi.org/10.1007/s00262-002-0328-9
		[Y] - HARUO SUGIYAMA, "Saibo shuki to gan - WT1 tanpaku o hyoteki ni shita gan no men'eki ryoho -", BIOTHERAPY, (2000), vol. 14, no. 8, pages 789 - 795, XP002963476
		[Y] - YOSHIHIRO OKA ET AL., "3. Men'eki ryoho 2) WT1 o hyoteki to shita hakketsubyo ni taisuru tokuiteki men'eki ryoho", HEMATOLOGY FRONTIER, (2000), vol. 10, no. 8, pages 1017 - 1023, XP002963477
		[Y] - OKA Y. ET AL., "Cancer immunotherapy targeting Wilms' tumor gene WT1 product", J. IMMUNOL., (20000215), vol. 164, no. 4, pages 1873 - 1880, XP000890067
		[Y] - SUGIYAMA H. ET AL., "Wilms' tumor gene WT1: its oncogenic function and clinical application", INT. J. HEMATOL., (200102), vol. 73, pages 177 - 187, XP002963478
		[Y] - LIN R. ET AL., "Present status of the use of cytokines as adjuvants with vaccines to protect against infectious diseases", CLIN. INFECT. DIS., (199512), vol. 21, no. 6, pages 1439 - 1449, XP000576631
		[Y] - YOSHIRO TANIO ET AL., "Men'eki kyoka busshitsu", JAPANESE JOURNAL OF CANCER AND CHEMOTHERAPY, (1980), vol. 7, no. 9, pages 1710 - 1718, XP002963479
		[Y] - ICHIRO HIGASHI, "BRM to shite no saikin kintai seibun", BIOMEDICINE & THERAPEUTICS, (1988), vol. 20, no. 1, pages 21 - 26, XP002963480
	Examination	GB2210557
		- SHOUTARO TSUJI ET AL, "Maturation of human dendritic cells by Cell Wall Skeleton of Mycobacterium bovis Bacillul Calmette-Guérin: Involvement of Toll-Like receptors.", INFECTION AND IMMUNITY, (200012), vol. 68, no. 12, pages 6883 - 6890

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p